TRUMP Boosts Experimental PSYCHEDELIC DRUGS as LSD. Carlson pressed him on Covid Vaccines DEATHS (videos). MD warns on Psychiatric Pharmas Damages as Akathisia
Introduction by Fabio Giuseppe Carlo Carisio
Trump’s Schizophrenic Management of Experimental Drugs and Big Pharma
US President Donald Trump’s move to accelerate the market launch of disturbing and experimental psychedelic drugs is set to cause an outcry not only in the US but also around the world.
This is yet another schizophrenic decision by Trump, now suspected of having dementia even by the mainstream media. On the one hand, he wages war on certain drugs, including pediatric vaccines due to a known link to autism, consistently denied by global health authorities. On the other, he prides himself on having funded Operation Warp Speed.
This granting allowed Big Pharma Moderna to rapidly market its mRNA genetic serum for the alleged prevention of Covid-19.
The mRNA genetic serum was patented months before the pandemic by the pharmaceutical company with the help of the military agency DARPA and Anthony Fauci, both suspected of having created SARS-CoV-2 in a laboratory.
On the one hand, he calls vaccines poisonous, and on the other, he sponsors Pfizer with $70 million in funding for other experimental drugs.
This deepens the suspicion that the American health policy on drugs is not being determined by the Secretary of the Department of Health and Human Sciences, Robert F. Kennedy Jr., but rather by White House Chief of Staff Susie Wiles, a renowned lobbyist for Big Pharma and the arms industry.
LOBBYIST of BIG PHARMA & WEAPONS as WHITE HOUSE Staff Chief. Trump’s First Step into NWO Hell
By a curious coincidence, the US president’s push for the most dangerous psychotropic drugs (LSD and magic fumes) comes just as an Australian doctor is raising the alarm about the dangers of psychiatric drug therapies, and in particular the new pathology named akathisia.
Precisely to highlight Trump’s contradictions in managing Big Pharma’s experimental pharmaceutical products, before delving into the scientific issues, we publish the outburst by American journalist Tucker Carlson in which he accuses the POTUS of not wanting to address the topic of deaths caused by the Covid-19 vaccines hastily funded by Trump himself at the end of his first term.
Tucker Carlson PRESSED President Trump on the COVID-19 Vaccine
“You know what he said to me? I actually raised it with him because I’m so upset about it. It’s actually killed too many people and made too many women infertile, and it’s just the most evil thing ever. It’s so immoral…”
“He did the same thing he did on the Iran War… He’s like, ‘You don’t believe in the polio vaccine? Like, that was a good vaccine, don’t you think?’” added the journalist.
“It’s like I guess… but that’s not what we’re talking about. The polio vaccine is a totally different thing. It was a non sequitur designed to shut down the conversation.” Carlson concluded.
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster
by Nick Paul Tailor – Originally published by FiercePharma
All Gospa News links or Video have been added in the aftermath by virtue of ties with covered topics
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push to clear barriers to access to treatments for serious mental illnesses.
Psychedelic Drugs such as LSD and the active ingredient in magic mushrooms.
The executive order tasks the FDA with giving Commissioner’s National Priority Vouchers “to appropriate psychedelic drugs” with Breakthrough Therapy designations.
At a press conference about the order on Saturday, FDA Commissioner Marty Makary said the agency will soon issue priority review vouchers to three serotonin 2a agonists, a class that covers psychedelics such as LSD and the active ingredient in magic mushrooms.
Makary has yet to reveal which companies will receive the vouchers. Still, the announcement was warmly received by U.K.-headquartered Compass Pathways, which is developing a synthetic form of psilocybin, a molecule found in magic mushrooms.
“We commend the administration’s executive order on psychedelic treatment, which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” Compass CEO Kabir Nath said in an April 18 statement.
“Today’s announcement aligns regulatory urgency with patient need, and we applaud the administration for taking this important step forward in accelerating access, without compromising rigorous science.”
Nasdaq-listed Compass reported another phase 3 win for its candidate, COMP360, in treatment-resistant depression in February. The company is working with the FDA on a rolling approval submission that, as of last month, it was on track to complete in the fourth quarter.
Definium Therapeutics, which plans to publish data this year from three phase 3 trials of its formulation of LSD, also “applaud[ed]” the executive order.
Trump named the Ibocaine
Trump ordered the FDA and the Drug Enforcement Administration to establish a pathway for patients to access investigational psychedelic drugs that are under FDA review. The president named ibogaine compounds as psychedelic drugs that could be accessed via the pathway.
Ibogaine is a naturally occurring psychedelic drug that researchers have studied as a potential treatment for opioid dependence and for depression and anxiety among veterans with traumatic brain injuries.
The podcaster Joe Rogan recently discussed ibogaine in a conversation with the U.S. Health Secretary Robert F. Kennedy Jr., noting that Texas had passed (PDF) a law to support studies of the psychedelic.
Rogan was at the Oval Office press conference for the signing of the executive order. The podcaster said he recently sent data on ibogaine use in opioid dependence to Trump. According to Rogan, the president replied: “Sounds great. Do you want FDA approval? Let’s do it.”
Originally published by FiercePharma
Akathisia: the hidden risk of psychiatric medication
by Marianne Demasi, PhD – Originally published on her Substack
Recently, podcaster Mikhaila Peterson released a video updating viewers on her father, Dr Jordan Peterson, who she says suffered a severe medication-related injury.
In 2020, Dr Peterson was prescribed the benzodiazepine ‘clonazepam’ during a period of intense personal stress.
According to his family, the medication triggered a prolonged and debilitating reaction that left him with ongoing neurological symptoms.
In her latest update, his daughter says those symptoms have returned, despite him having been off the medication for years.
She describes episodes of akathisia—an extreme state of inner agitation—in stark terms: “the worst thing I’ve ever seen anyone go through… intolerable discomfort that makes people want to crawl out of their skin.”
She also recounts her own experience after stopping an SSRI antidepressant, saying the withdrawal lasted more than two years and left her, at times, unable to function.
Her account is confronting, but it is not unique. It reflects a pattern that has been described for decades and is often under-recognised.
The first time I heard about it
I first came across akathisia more than a decade ago while working on a documentary about antidepressants for the Australian Broadcasting Corporation (ABC TV).
I interviewed patients, as well as psychiatrists and researchers from around the world.
Many patients who had tried to reduce or stop their medications reported a cluster of symptoms—marked agitation, insomnia, and anxiety—that did not fit a straightforward relapse of their original condition.
In one conversation, a patient described the sensation as “unbearable,” saying she felt an urge to jump out of her skin and that it induced suicidal thoughts. The account was consistent with what others reported.
The documentary was researched for months, interviews were completed, and scripts were written. It reached the final stages in the edit suite before being pulled at the last minute.
The network was concerned about the public’s reaction—specifically, that the program might lead some viewers to question their medication, or even stop it—despite repeated messaging that these drugs should not be stopped abruptly and require medical supervision.
That decision censored real patient experiences from the public—especially those that challenged prevailing clinical assumptions.
What is akathisia?
Akathisia is still often described in clinical settings as “restlessness.”
But that description fails to capture the reality of the patient experience. It is a severe, whole-body state of inner agitation.
It has been described in medical journals as “an intense inner restlessness and a compelling need to be in constant motion,” often accompanied by marked distress and an inability to remain seated.
Case reports describe a feeling of terror, a persistent sense of dread, and an urgent need to escape one’s own body.
This is why akathisia has been associated with suicidal ideation—not necessarily driven by depression, but because the sensation becomes unbearable, and death is perceived as a means of escape.
In some cases, symptoms can persist—a pattern now described in the literature as benzodiazepine-induced neurological dysfunction, or BIND, where neurological and psychological symptoms can continue for months or even years after the drug is stopped.
This has been described in cases like Peterson’s. Akathisia is not limited to benzodiazepines.
FULL ARTICLE CONTINUES ON THE DEMASI SUBSTACK
by Marianne Demasi, PhD – Originally published on her Substack
RELATED POSTS
